Altimmune, Inc. SEC Filings

Altimmune, Inc. has released its 2026 proxy for a virtual annual meeting on April 16, 2026. Shareholders of record as of March 13, 2026, when 130,105,177 common shares were entitled to vote, are asked to elect nine directors and ratify Ernst & Young LLP as auditor.

Investors will also cast an advisory vote on executive pay, consider doubling authorized common stock from 200,000,000 to 400,000,000 shares, and vote on expanding the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares. A proposal to allow adjournment to solicit more proxies is also included.

Altimmune, Inc. Chief Financial Officer Gregory L. Weaver bought 5,000 shares of the company’s common stock in an open-market purchase at a price of $3.54 per share. After this transaction, he directly owns 28,078 common shares of Altimmune.

Altimmune, Inc. director, President and CEO Jerome Benedict Durso reported an open-market purchase of 20,000 shares of common stock. The shares were bought at a weighted average price of $3.5395 per share in multiple trades between $3.53 and $3.55.

Following this transaction, Durso now directly owns 32,500 shares of Altimmune common stock. The purchase reflects an increase in his direct equity stake through open-market buying.

Altimmune, Inc. will hold its 2026 virtual Annual Meeting on April 16, 2026 (8:30 a.m. ET); the record date was March 13, 2026. Stockholders will vote on six proposals: election of nine directors; ratification of Ernst & Young LLP as auditor; an advisory "say-on-pay" vote; an amendment to increase authorized common stock from 200,000,000 to 400,000,000; an amendment to the 2019 Employee Stock Purchase Plan to increase the reserve to 1,108,827 shares; and authorization to adjourn.

The proxy materials state there were 130,069,983 shares issued and outstanding as of March 1, 2026, 17,226,344 shares issuable under an at-the-market offering and 18,720,227 shares issuable or available under incentive plans; if issued, those would total 166,016,554 shares outstanding, leaving 33,983,446 authorized but unissued under the current charter. The Board recommends voting FOR all proposals.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on serious liver diseases, led by its dual glucagon/GLP‑1 agonist pemvidutide for MASH, alcohol use disorder and alcohol‑associated liver disease. More than 700 patients have received pemvidutide across 8 completed and 2 ongoing studies.

In the IMPACT Phase 2b MASH trial, 24‑week data showed MASH resolution without worsening fibrosis in 58.2% and 52.1% of patients on pemvidutide 1.2 mg and 1.8 mg, versus 19.9% on placebo, and significant improvements in non‑invasive fibrosis markers. Pemvidutide has Breakthrough Therapy and Fast Track designations for MASH.

For 2025, Altimmune reported a net loss of $88.1 million, improving from a $95.1 million loss in 2024, as research and development expenses fell 19% to $66.4 million while general and administrative costs rose 34% to $28.1 million. Cash, cash equivalents, restricted cash and short‑term investments were $273.5 million as of December 31, 2025, and management believes this will fund operations for at least twelve months from the financial statement issuance date.

Altimmune, Inc. reported 2025 results showing it remains a late-stage clinical biopharma focused on pemvidutide for serious liver diseases. For 2025, the company recorded a net loss of $88.1 million, improving from $95.1 million in 2024, as research and development spending fell to $66.4 million from $82.2 million. General and administrative expenses rose to $28.1 million from $21.0 million. Net loss per share narrowed to $1.00 from $1.34, on higher weighted-average shares.

Altimmune ended 2025 with $274.0 million in cash, cash equivalents and short-term investments and subsequently strengthened its balance sheet with a $75 million registered direct offering in January 2026 and a noncurrent term loan of $34.3 million. The lead asset pemvidutide received FDA Breakthrough Therapy Designation for MASH and Fast Track designations for MASH and AUD. The company plans to initiate a Phase 3 MASH trial in 2026 and expects topline data from its Phase 2 pemvidutide trial in alcohol use disorder in the third quarter of 2026, while a Phase 2 trial in AUD and the RESTORE trial in alcohol-associated liver disease continue.

Altimmune, Inc. Chief Scientific Officer M Scot Roberts reported equity awards consisting of stock options and restricted stock units. He was granted 222,670 stock options with an exercise price of $0.0000 per share, all held as direct ownership.

The options vest over four years, with 25% vesting on February 26, 2027 and the rest vesting in equal monthly installments over the following 36 months, subject to continued service. Roberts also received 95,430 restricted stock units, each representing one share of common stock when vested.

The RSUs vest over four years, with 25% vesting on February 26, 2027 and the remaining units vesting in equal annual installments over the next three years, contingent on his continued service. These awards reflect non-cash compensation rather than open-market share purchases or sales.

WEAVER GREGORY L reported acquisition or exercise transactions in this Form 4 filing.

Altimmune, Inc. reported that its Chief Financial Officer, Gregory L. Weaver, was granted stock-based awards on February 26, 2026. He received stock options covering 259,000 shares of common stock and 111,000 Restricted Stock Units (RSUs), both held as direct ownership.

The option grant vests over four years, with 25% of the shares vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, subject to his continued service. Each RSU represents a contingent right to receive one share of common stock and vests over four years, with 25% of the RSUs vesting on February 26, 2027 and the remainder in equal annual installments over the next three years, also subject to continued service.